Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population

• Published in: International journal of molecular sciences 2023-11, Vol.24 (21), p.15837
• Main Authors: Dalbeni, Andrea, Garbin, Marta, Zoncapè, Mirko, Romeo, Sara, Cattazzo, Filippo, Mantovani, Anna, Cespiati, Annalisa, Fracanzani, Anna Ludovica, Tsochatzis, Emmanouil, Sacerdoti, David, Mantovani, Alessandro, Lombardi, Rosa
• Format: Article
• Language: English
• Subjects: Adult; Chronic kidney failure; Development and progression; Diabetes; Fatty Liver - complications; Female; Fibrosis; Humans; Hypertension; Insulin resistance; Kidney diseases; Liver Cirrhosis - etiology; Liver diseases; Male; Metabolism; Middle Aged; Mortality; Obesity; Pediatrics; Renal Insufficiency, Chronic - complications; Risk Factors; Type 2 diabetes
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242115837

Glomerular hyperfiltration (GH) is an increase in the glomerular filtration rate, possibly progressing to chronic kidney disease (CKD). Metabolic-associated steatotic liver disease (MASLD) is linked to an increased risk of CKD, especially if fibrosis is present; however, the association between GH and MASLD has not been explored. To evaluate GH prevalence in MASLD and its possible correlation with liver fibrosis. 772 consecutive patients with ultrasound MASLD (mean age 47.3 ± 8.9 years, 67.1% males) were enrolled. GH was defined as estimated glomerular filtration rate (eGFR) greater than the upper quartile of values in the cohort. Liver stiffness measurement (LSM) by FibroScan ≥ 7.2 kPa suggested liver fibrosis. GH was present in 20% of patients, liver fibrosis in 30%. In total, 53.4% of the cohort was obese, 40.9% hypertensive, 36.3% diabetic and 70.8% dyslipidaemic. GH patients compared to non-GH were significantly younger (38.4 ± 8.3 vs. 49.5 ± 7.7, < 0.001), with higher prevalence of LSM > 7.2 kPa (35.5% vs. 29%, < 0.001), without any difference in metabolic comorbidities. In multivariate analysis, age (OR 0.85, CI 95% 0.82-0.87) and significant fibrosis (OR 1.83; CI 95%1.10-3.03) remained independently associated with GH, regardless of the presence of metabolic alterations and nephrotoxic drugs. GH, an early marker of renal damage, is highly prevalent in MASLD and is associated with hepatic fibrosis. GH may be considered an early marker of both liver and renal disease and its recognition could prompt the management of risk factors aimed at preventing the progression of both hepatic and renal disease.